Table 1.
The use of MSCs in the treatment of different autoimmune diseases.
| Disease Type | Patients | Mesenchymal stem cell source | Administration Route | Results |
|---|---|---|---|---|
| Acute GvHD | 55 | Allogenic BM | IVI | 30 patients improved |
| AcuteGvHD | 1 | Allogenic BM | IVI | Improved skin, gut, and liver |
| Scleroderma | 1 | Allogenic BM | IVI | Improved condition |
| Multiple sclerosis | 3 | Allogous and autologous fat | Mixed IVI and intrathecal | Clinical findingsimproved; MRI unchanged |
| Crohn’s fistulae | 4 | Autologous fat | Intrafistula | 75L% closure |
| Lupus nephritis | 16 | Allogenic UC | IVI | SLEDAI renal function improved |
| Systematic lupus nephritis | 2 | Autologous BM | IVI | No change |